Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07527923 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

Study acronym: AURA-AD
StatusRecruiting
PhasePhase 1
Started2026-05-22
View on ClinicalTrials.gov ↗

Amendment history

2026-09-26
Trial sites expanded: 1 → 5 locations
2026-06-22
Study Status, Oversight, Study Description, Study Design, Outcome Measures, Contacts/Locations v1
Recruitment opened
Primary completion date2028-06-09→2028-06-23
Completion date2028-06-09→2028-06-23
Start dateestimated 2026-05-04→confirmed 2026-05-22
Enrollment target136→144
Study sites0→1
Secondary endpoints25 entries, revised
Absolute change from baseline in % Body Surface Area (BSA) Absolute change from baseline in EASI Percent change from baseline in % BSA Percent change from baseline in EASI
2026-04-07
Original filing
Regeneron
148 trials monitored
See 16 trials at risk
Atopic Dermatitis
489 trials monitored
See 14 trials at risk
This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans. The study is looking at: * What side effects REGN20423 might cause * How much REGN20423 is in the blood at different times * How well REGN20423 works in adults with atopic dermatitis * Whether the body makes antibodies against REGN20423 * How the body changes after having REGN20423, which can help researchers understand why REGN20423 works better in some people than others * What the best dose of REGN20423 is
Trial Details
NCT Number NCT07527923
Lead Sponsor Regeneron Pharmaceuticals
Conditions Healthy Volunteer, Atopic Dermatitis
Enrollment 144 participants
Start Date 2026-05-22
Primary Completion 2028-06-23 (estimated)
Study Completion 2028-06-23 (estimated)
Updated on ClinicalTrials.gov 2026-09-25